Fig. 4From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaMean (95% CI) change from baseline in ETDRS calculated BCVA score (FAS). FAS, full analysis set; LDD, last dose date; LOCF, last observation carried forwardBack to article page